Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
2001

Prognostic Factors in Lung Cancer Treatment

Sample size: 549 publication Evidence: moderate

Author Information

Author(s): Ataman Ö U, Bentzen S M, Saunders M I, Dische S

Primary Institution: Gray Cancer Institute, Mount Vernon Hospital Northwood, Middlesex, UK

Hypothesis

The study aims to identify failure-specific prognostic factors in non-small-cell lung cancer.

Conclusion

The study found that certain factors, such as treatment type and age, influence the time until failure in lung cancer patients.

Supporting Evidence

  • Randomization to CHART was associated with a prolonged interval to failure.
  • Increasing age was linked to a longer time until failure.
  • Female sex showed a trend towards a longer interval to failure.
  • Advanced clinical stage was associated with a decreased interval to failure.
  • Patients with advanced stage had a higher risk of distant failure.

Takeaway

This study looked at how different factors affect the success of lung cancer treatments, helping doctors understand which patients might need more help.

Methodology

The study analyzed clinical outcomes using a competing risk analysis with a log-logistic hazard function.

Participant Demographics

The study included 549 patients with non-small-cell lung cancer.

Statistical Information

P-Value

p=0.005 for CHART treatment, p=0.036 for age, p=0.09 for female sex, p=0.004 for advanced stage, p=0.009 for distant failure risk.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1054/bjoc.2001.2049

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication